Therapy Detail

Therapy Name Leucovorin
Synonym
Therapy Description

Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Leucovorin Wellcovorin Calcium folinate|Calcium citrovorum factor|folinic acid Chemotherapy - Antimetabolite 10 Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01535053 Phase III Leucovorin Dactinomycin Methotrexate Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting
NCT00550992 Phase I Busulfan Melphalan Mercaptopurine Cytarabine + Etoposide + Mitoxantrone Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Thioguanine Cyclosporine anti-thymocyte globulin Daunorubicin Leucovorin Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia Unknown status
NCT02620423 Phase I Gemcitabine Fluorouracil Irinotecan Reolysin Leucovorin Pembrolizumab Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma Completed
NCT03387098 Phase Ib/II GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting
NCT02883049 Phase III Dasatinib Dexamethasone + Doxorubicin Prednisone Vincristine Thioguanine Cytarabine Mercaptopurine Leucovorin Methotrexate Pegaspargase Etoposide Clofarabine Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Suspended
NCT00267865 Phase II Rituximab Methotrexate Leucovorin Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma Recruiting
NCT00293475 Phase Ib/II Filgrastim Pegfilgrastim Leucovorin Carboplatin + Methotrexate + Rituximab Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL Recruiting
NCT03020030 Phase III Nelarabine Dexrazoxane Asparaginase Vincristine Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting
NCT02043587 Phase II Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Etoposide Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Active, not recruiting
NCT03136406 Phase Ib/II GI-4000 Leucovorin Avelumab Nab-paclitaxel Bevacizumab Cyclophosphamide Capecitabine Oxaliplatin Fluorouracil ETBX-011 ALT-803 QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting
NCT01467115 Phase II Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER Completed
NCT02427620 Phase II Cyclophosphamide + Doxorubicin + Vincristine Filgrastim Dexamethasone Cytarabine + Methotrexate Leucovorin A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma Active, not recruiting
NCT01256398 Phase II Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting
NCT02112916 Phase III Cyclophosphamide Vincristine Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Suspended
NCT02723994 Phase II Prednisone Dexamethasone + Doxorubicin Leucovorin Mercaptopurine + Thioguanine Asparaginase + Cytarabine Ruxolitinib Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Recruiting
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Not yet recruiting
NCT03007147 Phase III Pegaspargase Methotrexate Leucovorin Cytarabine Mercaptopurine Thioguanine Vincristine Cyclophosphamide Imatinib Ifosfamide Dexrazoxane Daunorubicin Dexamethasone Methylprednisolone Etoposide Prednisolone Doxorubicin Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting
NCT01775501 Phase II Sorafenib Fluorouracil Oxaliplatin Leucovorin Sorafenib + mFOLFOX for Hepatocellular Carcinoma Active, not recruiting
NCT01424982 Phase II Pegfilgrastim Cytarabine + Methotrexate + Ponatinib Ponatinib + Vincristine Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Leucovorin Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT02138617 Phase II Leucovorin Bevacizumab Irinotecan Fluorouracil Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Recruiting
NCT03387111 Phase Ib/II Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Active, not recruiting
NCT02553460 Phase II Cyclophosphamide Mitoxantrone Dexamethasone Bortezomib Etoposide Vincristine Pegaspargase Vorinostat Cytarabine Methotrexate Leucovorin Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I Recruiting
NCT03387085 Phase Ib/II ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 QUILT-3.067: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting